Tiny Madrigal’s stock is soaring as it advances an experimental drug targeting NASH

Madrigal Pharmaceuticals can’t stay hidden in West Conshohocken much longer.

The 7-year-old company has experienced a rapid rise in its stock price and market capitalization, which at the start of the week was at $4.4 billion. That’s billion, with a “b,” for a company with just 10 employees, writes John George in the Philadelphia Business Journal.

[uam_ad id=”54865″]

Madrigal is going up against the big boys and helping the small firm has been the advancement and success in clinical trials for treatments for NASH — nonalcoholic steatohepatitis. NASH is a liver disease that affects 20 million people in the country.

“We were flying under the radar before,” said Paul Friedman, Madrigal’s CEO. “Now we are a known entity even though we are small because NASH is such a big area right now.”

Dr. Dina Halegoua-De Marzio, director of Thomas Jefferson University Hospital’s Fatty Liver Center, said about 20 potential treatments for NASH are in various stages of development.

To read the complete story click here.

[uam_ad id=”54875″]